Telerehabilitation After Zone 1 and 2 Flexor Tendon Repairs: Comparison With In-Person Therapy.

Telerehabilitation After Zone 1 and 2 Flexor Tendon Repairs: Comparison With In-Person Therapy.

Publication date: Jun 17, 2025

Telerehabilitation (TR) gained prominence during the COVID-19 pandemic, showing promising outcomes for remote hand therapy tendon repairs. This study compares remote and in-person hand therapy outcomes for flexor tendon repairs. This prospective, nonrandomized comparative clinical study included 23 patients, 25 fingers with flexor tendon repairs in zones 1 and 2. Participants were divided into 2 groups: telerehabilitation (TR) group, 9 patients (10 fingers), and in-person therapy (IP) group, 14 patients (15 fingers). All surgeries were performed under wide-awake anesthesia, followed by early controlled active motion therapy with a dorsal blocking orthosis. Telerehabilitation sessions were conducted via a smartphone video conferencing app. Total active motion (TAM) and disability levels (the Disabilities of the Arm, Shoulder, and Hand Questionnaire [DASH]) were evaluated at 6, 8, and 12 weeks postoperatively. Groups were compared based on TAM scores, DASH scores, and extension deficit degrees. The TR group included 3 women (33. 3%) and the IP group did 6 women (42. 9%) while median age was 27 years in TR and 33 years in IP group. Both groups showed significant improvements in TAM and DASH scores over time (P < .001). There were no significant differences between the TR and IP groups at each assessment in DASH scores, TAM scores, and extensor deficit degrees (P > .05). Clinical outcomes indicate that remote and in-person hand therapy provide similar results for patients with flexor tendon repairs in zones 1 and 2. Telerehabilitation is a viable alternative to traditional hand therapy and can be integrated into clinical practice due to its comparable results.

Concepts Keywords
Awake flexor tendon
Pandemic hand therapy
Smartphone telerehabilitation
Therapy WALANT
Weeks

Semantics

Type Source Name
disease MESH COVID-19 pandemic

Original Article

(Visited 1 times, 1 visits today)